IVIg-induced headache: prospective study of a large cohort with neurological disorders
Authors:
- Buse Rahime Hasırcı BayırBBBuse Rahime Hasırcı Bayır
- Miraç Ayşen ÜnsalMÜMiraç Ayşen Ünsal
- Cansu AğırcanCACansu Ağırcan
- Tuba Cerrahoğlu ŞirinTŞTuba Cerrahoğlu Şirin
- Onur AkanOAOnur Akan
- Gizem GürsoyGGGizem Gürsoy
- Tuğba EyigürbüzTETuğba Eyigürbüz
- Dilara Mermi DibekDDDilara Mermi Dibek
- Gönül AkdağGAGönül Akdağ
- Ayşe Deniz ElmalıAEAyşe Deniz Elmalı
- Ezgi NazlıENEzgi Nazlı
- Fatma Akkoyun ArıkanFAFatma Akkoyun Arıkan
- 11 March 2023
- journal article
- research article
- Published by Springer Nature in Neurological Sciences
- Vol. 44 (8) , 2871-2881
Abstract
Background Intravenous immune globulin (IVIg) is frequently used in some neurological diseases and is also the first-line therapy in Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy. We aimed to evaluate the frequency and characteristics of headaches, which is one of the most common side effects of IVIg treatment. Methods Patients who received IVIg treatment for neurological diseases were prospectively enrolled in 23 centers. Firstly, the characteristics of patients with and without IVIg-induced headaches were analyzed statistically. Then, patients with IVIg-induced headaches were classified into three subgroups determined by their history: no primary headache, tension-type headache (TTH), and migraine. Results A total of 464 patients (214 women) and 1548 IVIg infusions were enrolled between January and August 2022. The frequency of IVIg-related headaches was 27.37% (127/464). A binary logistic regression analysis performed with significant clinical features disclosed that female sex and fatigue as a side effect were statistically more common in the IVIg-induced headache group. IVIg-related headache duration was long and affected daily living activities more in patients with migraine compared to no primary headache and TTH groups (p = 0.01, respectively). Conclusion Headache is more likely to occur in female patients receiving IVIg and those who develop fatigue as a side effect during the infusion. Clinicians’ awareness of IVIg-related headache characteristics, especially in patients with migraine, may increase treatment compliance.Keywords
This publication has 21 references indexed in Scilit:
- Evidence-Based Strategies to Reduce Intravenous Immunoglobulin–Induced HeadachesAnnals of Pharmacotherapy, 2015
- Adverse Effects of Human Immunoglobulin TherapyTransfusion Medicine Reviews, 2013
- The International Classification of Headache Disorders, 3rd edition (beta version)Cephalalgia, 2013
- Tolerability of a New 10% Liquid Immunoglobulin for Intravenous Use, Privigen®, at Different Infusion RatesJournal of Clinical Immunology, 2010
- Safety of high-dose intravenous immunoglobulin in systemic autoimmune diseasesClinical Rheumatology, 2007
- A prospective study of the immediate and delayed adverse events following intravenous immunoglobulin infusionsArchives of Disease in Childhood, 2006
- Comparison of different brands of IVIg in an in vitro model of immune neuropathyJournal of Neuroimmunology, 2006
- Long term safety of IVIg therapy in multiple sclerosis: 10 years experienceAutoimmunity, 2006
- Posterior Reversible Encephalopathy Complicating Intravenous Immunoglobulins in a Patient with Miller-Fisher SyndromeEuropean Neurology, 2005
- Side effects of intravenous immunoglobulins in neurological autoimmune disordersJournal of Neurology, 2003